David Sparlin, APRN CNS | |
2328 Emily Lane, Purcell, OK 73080-0308 | |
(405) 990-2995 | |
Not Available |
Full Name | David Sparlin |
---|---|
Gender | Male |
Speciality | |
Experience | Years |
Location | 2328 Emily Lane, Purcell, Oklahoma |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1962800466 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
364S00000X | Clinical Nurse Specialist | 101973 (Oklahoma) | Primary |
Mailing Address | Practice Location Address |
---|---|
David Sparlin, APRN CNS Po Box 308, Purcell, OK 73080-0308 Ph: (405) 990-2995 | David Sparlin, APRN CNS 2328 Emily Lane, Purcell, OK 73080-0308 Ph: (405) 990-2995 |
News Archive
People are living longer with and after a cancer diagnosis, making survivorship clinics and programs-as well as official guidelines and practices governing the care of survivors-an important emerging component of modern cancer care. Many institutions are looking to gather these resources into an easily understandable plan for their survivors.
Survival rates for breast cancer in older women could be significantly improved by a simple awareness programme that promotes early presentation of the disease, according to results of the first trial of its kind presented at the National Cancer Research Institute Conference in Birmingham today (Sunday).
With the number of confirmed dengue fever cases in north Queensland now thought to be in excess of 200, experts are concerned that the mosquitoes responsible for spreading the disease may have developed a resistance to pesticides.
A new analysis indicates that death rates and the need for additional operations following laparoscopic surgery for gastro-oesophageal reflux disease are very low.
Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, today announced updated clinical data on CAL-101, the Company's oral, delta selective PI3K inhibitor, presented during two oral presentations at the 51st American Society of Hematology Annual Meeting in New Orleans.
› Verified 2 days ago